DENTSPLY SIRONA Inc.'s SEC filings document regulatory disclosures for a diversified dental products and technology manufacturer listed on Nasdaq under XRAY. Recent Form 8-K reports furnish operating results, GAAP and non-GAAP reconciliations, outlook commentary, distribution agreements, product and regulatory updates, restructuring actions and capital allocation changes involving dividend policy, debt reduction and share repurchases.
The company's proxy and governance filings cover director elections, board composition, committee assignments, executive compensation and stockholder meeting matters. Other current reports disclose board expansion, director appointments, chief financial officer transition matters, separation arrangements and Regulation FD communications tied to commercial agreements and corporate updates.
BlackRock, Inc. reported beneficial ownership of 25,295,015 shares of DENTSPLY SIRONA INC common stock, representing 12.6% of the class as of 06/30/2026. The filing shows sole voting power over 24,804,969 shares and sole dispositive power over 25,295,015 shares.
MAZELSKY JONATHAN JAY reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky received a compensation grant of phantom stock units tied to the company’s common stock. On this Form 4, he was awarded 2,841.8303 shares of phantom stock at $10.56 per share, each economically equivalent to one share of common stock. Following this award, his total phantom stock balance is 20,021.6843 units, which will be settled in common stock after his service as a director ends. This is a non-cash, deferred compensation transaction rather than an open-market stock purchase or sale.
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky filed an amended insider report clarifying that a recent transaction was an open-market stock purchase. On this amended Form 4, he is shown buying 10,000 shares of common stock at $10.14 per share. Following this transaction, his direct ownership stands at 61,668.534 shares of DENTSPLY SIRONA common stock. The amendment corrects the original coding of the trade, which had been mistakenly reported as an award rather than a market purchase, while leaving all other details unchanged.
DENTSPLY SIRONA Inc. executive Lindi Rene Barton-Brobst, SVP, GC & Secretary, filed an initial statement of beneficial ownership. She reports 45,185.444 shares of common stock held directly, including 38,743.444 Restricted Stock Units, plus 254.6498 shares held indirectly through a 401(k) plan.
She also holds phantom stock representing 556.7220 equivalent common shares under a Supplemental Executive Retirement Plan, payable in stock upon termination of employment, and multiple stock option grants to buy common shares at exercise prices between $14.7800 and $58.7100 with expirations from 2030 to 2036. The filing lists these positions as holdings rather than reporting new purchases or sales.
DENTSPLY SIRONA Inc. director Clyde Hosein made an open-market purchase of 6,500 shares of common stock at $9.985 per share. Following this transaction, his direct ownership increased to 70,575.456 shares, indicating a higher personal equity stake in the company.
DENTSPLY SIRONA Inc. director Brian P. McKeon reported an open-market purchase of the company’s common stock. On June 12, 2026, a trust associated with him bought 10,000 shares at $10.12 per share, held as indirect ownership. A separate entry shows he directly holds 28,887 common shares following the reported transactions.
DENTSPLY SIRONA Inc. director Brian T. Gladden reported an open-market purchase of 9,985.022 shares of common stock on June 15, 2026. The weighted average purchase price was $10.015 per share, based on multiple trades between $10.015 and $10.0156. Following this transaction, he directly owns 61,848.544 shares of the company’s common stock.
MAZELSKY JONATHAN JAY reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky received a grant of 10,000 shares of Common Stock on June 12, 2026 at a reported value of $10.14 per share. This compensation-related award increased his directly held stake to 61,668.534 shares, rather than reflecting an open-market purchase.
DENTSPLY SIRONA Inc. director Betsy D. Holden purchased additional shares of the company’s Common Stock in the open market. She bought 10,086 shares on June 11, 2026 at a weighted average price of $9.8842 per share. After this transaction, she directly owns 87,528 shares of DENTSPLY SIRONA Common Stock. The filing notes that the purchase price reflects multiple trades executed between $9.865 and $9.90 per share.
DENTSPLY SIRONA Inc. director Michael J. Barber reported an open-market purchase of Common Stock. On June 11, 2026, he bought 15,175 shares at a weighted average price of $9.885 per share, with individual trades ranging from $9.87 to $9.93. Following this transaction, he directly owns 55,943 shares of the company’s stock.